Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

JAK Inhibitors Could Face Scrutiny Over Cholesterol Effects

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

As positive efficacy data rolls in for the janus kinase inhibitors in rheumatoid arthritis, like Pfizer’s Phase III tasocitinib, elevated lipid levels are emerging as an issue worth keeping an eye on.

You may also be interested in...



US FDA Panel Weighs Design Of A Pre-approval Safety Study For Janssen's Sirukumab

IL-6 inhibitor should be compared to another biologic to exclude a multi-fold increase in the risk of death, advisers say; FDA assures the panel's industry representative it is not considering an across-the-board requirement for large safety studies of rheumatoid arthritis treatments.

JAK Of All Trades: Janus Kinase Inhibitors Are Ready, Willing And Orally Available For Many Diseases

Orally available, flexible and novel, Janus kinase inhibitors are poised to trigger major treatment shakeups in at least two disease spaces. Two drugs at the head of the JAK pack are close to coming of age – Pfizer Inc.’s tofacitinib and Incyte Corp.’s ‘18424 – and hopes are high, though questions remain about selectivity, long-term side effects and just how far the class can go.

JAK Of All Trades: Janus Kinase Inhibitors Are Ready, Willing And Orally Available For Many Diseases

Orally available, flexible and novel, Janus kinase inhibitors are poised to trigger major treatment shakeups in at least two disease spaces. Two drugs at the head of the JAK pack are close to coming of age – Pfizer Inc.’s tofacitinib and Incyte Corp.’s ‘18424 – and hopes are high, though questions remain about selectivity, long-term side effects and just how far the class can go.

Related Content

Topics

UsernamePublicRestriction

Register

PS012935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel